chrisvoncsefalvay/vaers-outcomes huggingface dataset:
loss of smell; Loss of taste; High fever; chills; sweats; Aches; fatigue; Swollen hard arm; Broke out with fever blisters nose mouth and lips; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727), via the unspecified route of administration in the right arm on 24Mar2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks of the COVID vaccination. The patient did not receive any medications within two weeks of the COVID-19 vaccination. On 25Mar2021 at 03:00, the patient experienced high fever, chills, sweats, aches, fatigue, swollen hard red arm for five-plus days, fever blisters in nose mouth and lips. On 28Mar2021 (day 5), the patient experienced the loss of smell and taste. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events high fever, chills, sweats, aches, fatigue was resolved in 48 hours on 27Mar2021; while the events of the swollen hard red arm, fever blisters, loss of smell and loss of taste was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
patient reported adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of ADVERSE EVENT (patient reported adverse event) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ADVERSE EVENT (patient reported adverse event). At the time of the report, ADVERSE EVENT (patient reported adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment information was provided.  The patient asked whether it hurts or not to take second booster or not.
Info has been received from a registered nurse concerning a 70 year old female with arthritis who on 08/01/2001 at 09:00 AM was vaccinated intramuscularly in the left deltoid with a 1st dose of pneumococcal vaccine 23 polyvalent (Lot #637263/1448K). On 08/01/2001 at 13:00 PM the pt developed a 3" x 4" area at the injection site consisting of swelling, redness and warmth. The pt developed a temperature of 100.4 F and also experienced malaise lasting for 4 days. On 08/10/2001 (also reported as day 7 following the injection) the pt was treated with amoxicillin trihydrate (+) clavulanate potassium (AUGMENTIN) for a "possible cellulitis" at the same site. It was reported on 08/20/2001 that all symptoms appeared to be resolved. On 08/12/2002 the registered nurse reported that the pt has recently reported that the same area "will become red and tender for short periods at 4-6 week intervals". It was also reported that the area becomes warm. No further info is expected.
Slurred speech; Aphasia; Irregular migraine provoked by vaccine; The evening of 16Feb2021, felt slightly dizzy with a moderate headache.; The evening of 16Feb2021, felt slightly dizzy with a moderate headache.; This is a spontaneous report from a contactable nurse, the patient. A 34-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246) via an unspecified route of administration in the left arm on 16Feb2021 at 16:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, anxiety, ruptured uterus with exsanguination, hypertension, COVID-19 and known allergy to sulfa. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient previously also received prednisone (MANUFACTURER UNKNOWN), celecoxib (CELEBREX) and gabapentin (MANUFACTURER UNKNOWN) on an unspecified date for an unknown indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included bupropion (MANUFACTURER UNKNOWN), venlafaxine (MANUFACTURER UNKNOWN) and topiramate (TOPAMAX); all for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 27Jan2021 at 12:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation.  On 16Feb2021 at 20:30, the evening of the day of vaccination, the patient felt slightly dizzy with a moderate headache. On 17Feb2021 at 06:30, after the patient woke up, the patient experienced slurred speech with aphasia, the patient was unable to speak clearly and the words that did come out were not the correct words. The patient was trying to convey and was taken to ER at that time. Diagnosis was an irregular migraine provoked by vaccine. On 17Feb2021, the patient underwent computerized tomography and magnetic resonance imaging scan and the results were negative. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department visit or urgent care. Therapeutic measures were taken as a result of the event which included emergency room visit, computerized tomography and magnetic resonance imaging scan and neurology appointment. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events felt slightly dizzy with a moderate headache, irregular migraine provoked by vaccine, slurred speech and aphasia was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
w/in 3-4hr p/vax pt devel severe h/a, muscle aches & muscle weakness, nausea-not able to walk around x/ to get to bathroom w/help;sx would go away 48hr then would be tired x 4-5 days;
Developed a large about 4 inch red swollen welt that felt warm to the touch. It seems to spread around the arm as the days go by. It does not itch me. The welt feel hard to the touch, but does not burn. It does not impair daily activities. But is slightly sensitive to the touch , and I did not have a sleeve covering the area. I had the same reaction with the first dose of the covid vacccine, and that welt lasted approx 3 weeks, and I still have a slight black and blue mark in that area. I did get the 2nd dose in the same arm as the first dose.
Patient is a 63-year-old man with no significant pre-existing illnesses does have a history of cigarette smoking.  Proximally 2 days ago developed cramping and discomfort in the right leg that has progressively worsened he now has numbness in the right lower leg and cool right lower leg with paresthesia.  I can palpate his femoral pulse however CTA indicates some clot in the distal aorta and the common iliac artery as well as essentially complete occlusion of the distal right external iliac and femoral and distal system.  Patient's history is significant and he does not have a known history of COVID-19 but did undergo vaccination 3 to 4 weeks ago with a Johnson & Johnson vaccine.  He reports no history of known heart disease lung disease renal disease or clotting disorders he takes no regular medications.ported to ER 8/12 with pain and thrombosis to rt iliofmoral popliteal artery with no history prior to this event,
This spontaneous case, was initially received from other health professional (nurse) on 05-Oct-2017, concerning a 38-year-old adult male patient. The patient's medical history was not reported. The patient did not receive any concomitant medications. On 03-Oct-2017, the patient was administered with FLUCELVAX QIV (dose: 0.5 ml, batch number: 195221, expiry date: Apr-2018, route of administration and anatomical location: not reported). The patient received the vaccine, which underwent temperature excursion (less than 32.54-degree F for about 25 hours) (explicitly coded as incorrect product storage and drug administration error). The reporter assessed the events as non-serious. Non-significant case correction received 05-Oct-2017: Batch number (195221) was captured in the case form and narrative was amended accordingly.
patient reports anxiety. heart rate was 100. patient asked to drink water, relax laid down with feet up. reassessed after 20 minutes. heart rate was down to 69 and oxygen 99%.
I am the epidemiologist reporting on behalf of 61-year-old female patient. The patient received two doses of the Pfizer vaccine on 1/29/21 and 2/19/21. The patient tested positive for COVID-19 on 8/10/21 via PCR. The patient died 9/1/21 and the cause of death is listed as ?ARDS Covid-19?. I do not have further information regarding immunodeficiency status or underlying health conditions.
The day of the vaccine I got really dizzy almost right away. I don't have problems with needles I'm usually find with shots. Then I was fine  After 2 days  I had loss of appetite, nausea, body aches and headaches.  The 3rd day same symptoms but got worse. 4th day I feel I'm doing better just some head pain
Patient received her Moderna vaccine. She waited the 15 minutes and went around the store to shop. She then started to feel sharp chest pain and shortness of breath and returned to pharmacy. Patient did not report swelling in the airways, was able to breathe however with some difficulty. Patient reported having history of asthma and high cholesterol when asked. With patients consent, took patients blood pressure and the reading was 130/87. Told daughter what was going on, most likely not an allergic reaction/anaphylaxis. Patient then started to have "pseudo-seizures." Asked daughter and patient if we can call ambulance, and they both agreed. Stood by patient in post-vaccination area waiting for ambulance. Patient was still able to breath and her chest pain has decreased per patient - said pain lessened when sitting down. Ambulance arrived and took patient away. Both daughter and patient thanked pharmacy for helping and taking care of patient.
Appox. 15 minutes after receiving 2nd dose of Pfizer Covid vaccine patient stated she has slight nausea and light headedness.  BP 133/88.  Patient states her sugar levels are low and needs something to eat, asked patient to wait another 15 minutes before leaving.  Patient ate a piece of fruit and stated she felt better.  She also stated this happens because of her Diabetes and she did not eat breakfast.
Felt dizzy; Her BP shot up high; This is a spontaneous report from a Pfizer-sponsored program from a contactable Nurse. A female patient of an unspecified age received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at SINGLE DOSE for COVID-19 vaccination. The patient's medical history and concomitant medications were not reported. The patient felt dizzy and her BP shot up high. The outcome of the events was unknown. Information on the lot/batch number has been requested.
Patient came in on 12/10/22 and notified the provider that the day of 6/23/22 when she received her Shingrix vaccine. After she left the clinic she was not feeling well. She ended up going to an ophthalmologist on 8/2/22. Provider at her 12/10/22 state she had developed a vitreous dis-attachement of her left eye from all they symptoms she mentioned hours after her vaccine. The ophthalmologist on 8/2/22 also stated that she had a  vitreous hemorrhage of her Left eye.
pt recvd 2 doses of Engerix-B & exp elevated liver tests p/the 1st dose; sl elevation persists; tx done;
sharp pain near injection site when I tried to raise my left arm; Injection arm soreness; pain in left arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (Injection arm soreness), MYALGIA (pain in left arm) and VACCINATION SITE PAIN (sharp pain near injection site when I tried to raise my left arm) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 009C21A and 009C21A) for COVID-19 vaccination.     The patient's past medical history included Movement disorder, Pain in arm and Muscle strain (right arm). Concurrent medical conditions included Fibromyalgia since 01-Jan-2000, Depression since 01-Jan-1980, Egg allergy, Food allergy (Allergy to whey), Seasonal allergy, Allergy to chemicals (Allergy to perfumes), Allergy to chemicals (Allergy to scents) and Allergy to chemicals (Allergy to Harsh chemicals). Concomitant products included FISH OIL from 01-Jan-2016 to an unknown date for Inflammation, MULTIVITAMINS [VITAMINS NOS] from 01-Jan-2018 to an unknown date, HCL PLUS [AMMONIUM CHLORIDE;BETAINE HYDROCHLORIDE;GLUTAMIC ACID HYDROCHLORIDE;PEPSIN;PYRIDOXINE HYDROCHLORIDE] from 01-Jan-2008 to an unknown date, BIO B COMPLEX from 01-Jan-2008 to an unknown date and ASTRAGALUS MONGHOLICUS ROOT (ASTRAGALUS EXTRACT) from 01-Jan-2015 to an unknown date for an unknown indication.   On 24-Apr-2021 at 11:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-May-2021 at 11:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-May-2021, the patient experienced MYALGIA (pain in left arm). On 06-May-2021, the patient experienced VACCINATION SITE PAIN (Injection arm soreness). On an unknown date, the patient experienced VACCINATION SITE PAIN (sharp pain near injection site when I tried to raise my left arm). On 20-May-2021, MYALGIA (pain in left arm) had resolved. At the time of the report, VACCINATION SITE PAIN (Injection arm soreness) and VACCINATION SITE PAIN (sharp pain near injection site when I tried to raise my left arm) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was provided   Most recent FOLLOW-UP information incorporated above includes: On 05-Jul-2021: Significant follow-up information received: Second dose information updated, Event outcome for pain in left arm was updated, Concomitant medications, ethnicity, race, height, weight, age at vaccination site, allergies, Primary Reporter's middle name, Vaccine facility information were updated.
Mild fever, chills, body aches, joint pain, nausea, fatigue, pain/swelling at injection site
1st day-A pinkish-red,  the size of a quarter +  headache +  slightly tired (I still took my normal 45-minute brisk walk) 2nd day-more reddish, size of a silver dollar + swelling (hardness) + tenderness + headache + mild dizziness (less stable when doing balance yoga-type exercises & I was able to swim for 20 minutes in the evening)  3rd day-pinkish red, size of a silver dollar, + less swelling, but still hardness + less tender (I took my normal walk & lifted light weights, so I'm able to do my normal activities.)   Taking 2 tabs of Ibuprofen seemed to do the trick to reduce headache & uncomfortableness on day 1 & 2. None taken today.
6-7 hours after injection my upper left arm was extremely red, swollen, warm and painful. I could not lift my arm without a great deal of effort and pain. I took liquid BENADRYL at that time and then again before bedtime.
Patient had no known side effects; Expired proquad was given; This spontaneous report has been received from a nurse referring to a 5 year old patient. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not provided.     On 29-MAR-2021, the patient was vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 ml, lot # S030211 with expiration date of 25-MAR-2021 (strength, route, frequency, anatomical location, lot # and expiration date were not provided) for prophylaxis. No adverse events reported.
VACCINE WITH AN OUT OF RANGE TEMPERATURE EXCURSION  AND WAS ADMINISTERED; A spontaneous report has been received from a health professional. The report concerns a patient of unknown gender (age not provided) of Unknown ethnic origin.    No medical history was reported. The following demography was reported for the patient's parent:   Sex: Unknown    No concomitant products were reported.    The patient received Flumist Quadrivalent (influenza vaccine live reassort 4v) (batch number PJ3267) (expiration date 26-DEC-2022), via nasal route, on 03-NOV-2022. The patient received Flumist Quadrivalent (influenza vaccine live reassort 4v), via nasal route, on an unknown date.     A UNKNOWN administered FLUMIST QUADRIVALENT. No malfunction has been reported for this combination product.   A UNKNOWN administered FLUMIST QUADRIVALENT. No malfunction has been reported for this combination product.    On an unknown date, the patient experienced vaccine with an out of range temperature excursion  and was administered (preferred term: Product storage error).     It is unknown if any action was taken with Flumist Quadrivalent (influenza vaccine live reassort 4v) and Flumist Quadrivalent (influenza vaccine live reassort 4v).     The outcome of the event was unknown.    The event was considered non-serious.     The reporter did not consider that there was a reasonable possibility of a causal relationship between Flumist Quadrivalent (influenza vaccine live reassort 4v) and the following event(s): vaccine with an out of range temperature excursion  and was administered. The reporter did not consider that there was a reasonable possibility of a causal relationship between Flumist Quadrivalent (influenza vaccine live reassort 4v) and the following event(s): vaccine with an out of range temperature excursion  and was administered.     Device Information:     Combination Product Report: Yes    Product As Reported: FLUMIST QUADRIVALENT  Common Device Name: Nasal Spray  Procode: CCQ  Product Role: Suspect    Product As Reported: FLUMIST QUADRIVALENT  Common Device Name: Nasal Spray  Procode: CCQ  Product Role: Suspect
My father was very healthy. He installed a very heavy door mid Feburary. He could walk 3-4 miles a day weather permitting. In early March, he couldn't catch his breath.  He went to see Dr. in March. Done an xray. Dr. said his lungs looked like a covid patient. Covid test negative. another xray in the summer. lungs looked a little better.  11/2021 more tests sent my dad to see dr.  He was put on 6L. More test coming. He was able to walk on his own in november to see the doctor. He can't walk to the garage without oxegen now. He has been rapidly declining. Please look at the medical evidence. It could help someone else
Pt is a 38 year old male who received both AVA # 1 and the typhoid vaccine on 14 Oct 04 in the am. When he got home that pm he noticed a few "hives" on his trunk that increased in number throughout the pm and was associated with slight itching. He denied, wheezing, SOB, swelling or GI symptoms. He stated he had hives before but they were not like this. When asked to describe the lesions he stated they were little red raised bumps approx 1-2 mm in size. He denied weeping, pustules, vesicles or welts. Stated they were just tiny red raised spots. He stated he had over 100 lesions that night and he took only one Benadryl. There was no worsening in the morning and after 2-4 days the lesions cleared and have not returned since. He stated he had no problems with swelling to his arm where shots were administered and he denied fever, and other systemic symptoms. He denies any triggers and has not had a reaction since. He is currently due for AVA and the typhoid vaccines in preparation for deployment.
Significant L arm soreness beginning at 9pm, chills throughout night, awoke frequently in the night, arose with fever.  Took Tylenol at 9am.
Vaccine administered at 10:41.  Monitored in vaccine clinic before returning to work area in PACU.  Upon return to PACU at 10:57, felt foggy and didn't feel right.  Employee sat down.  Left upper lip started to tingle, patient experienced palpitations and difficulty breathing, requiring surgical mask to be removed.  Code EMA (code for non-patient called).  Employee taken to emergency department for evaluation.
Vomiting, fever, high pitched cry for hours, headache, seizures 3 days later, unresponsiveness.
Apart from two days of aches etc which I have had after each covid vaccine and which went away, my neck arthritis has become chronic at times, despite physio and chiropractic treatment.
Fever 102 F for approximately 24 hours beginning ~15 hours post injection; severe headache and nausea for approximately 36 hours; fatigue and joint aches for 44 hours+
1 of 3 pt's exp swelling, pain @ inject site, & flu-like sx, beginning 24 hrs, post vax, & ending p/2 wks; tx APAP & ice packs;
Information has been received from a physician concerning a 13 year old female with no pertinent medical history and no known allergies who was vaccinated IM with the first 0.5 ml dose and the second 0.5 ml dose of GARDASIL (lot # of both doses not reported) on 15-JUN-2010 and 17-AUG-2010, respectively. There was no concomitant medication. On 24-AUG-2010, the patient experienced blurred vision, seeing spots and a headache. The physician reports that the patient was seen by an optometrist who performed vision exam and noted visual field deficits, and that patient was scheduled for an MRI on 26-AUG-2010. It was also reported that the patient had vision loss. At the time of the report, the patient was not recovered. Vision loss was considered to be disabling by the reporting physician. Additional information has been requested.
Case number PHEH2014US024437, is an initial spontaneous report received from a nurse on 04 Dec 2014 and with follow-up received from a nurse on 21 Jan 2015. This report refers to a 17 year old female patient. Concurrent conditions included smoking and occasional alcohol use. All previous vaccinations were well tolerated. The patient received MENVEO (batch number: M14030) at a dose of 0.5 ml into right deltoid intramuscularly on 05 Nov 2014 at 08:56. It was reported that the patient received MENVEO which had 27 temperature excursions more than 46 degree F with the temperature excursions lasting 30 minutes each time. No adverse event was reported. No further information was provided. Follow-up received from a nurse received on 21 Jan 2015: Patients demographics (height and weight), concurrent conditions, vaccine details (dose, site, date and time) were updated.
Chills and fatigue began around 11 hours post vaccine. A fever developed 2 hours following. The next day included a low grade fever the first hour of the morning, and nausea/loss of appetite the rest of the day. Muscle soreness was present all day.
Subjective fever and fatigue on 5/24 and 5/25. Erythema and pruritus at injection site starting 05/27/15. Advised to put cool compress to area and notify PCP.
Initial case received on 08 December 2009 from a physician. A 60 year old female patient received an intramuscular left deltoid injection of H1N1 (lot number UP015AA) on 08 December 2009. Five minutes post vaccination she complained of tightness in the chest lasting 10 seconds. She also developed a metallic taste in her mouth described as "continuous". No other symptoms were reported. The metallic taste was ongoing at the time of the report. Follow-up information was received on 11 January 2010 from a physician. The patient did not receive treatment and recovered from the metallic taste in her mouth. The reporter stated it was unknown if the patient was taking any other medications or had a history of chest tightness. Documents held by sender: none.
Pt received Menactra 4/22/05 @ 2 PM- at 6 PM pt developed fever 101.0, muscle aches, sore throat. SX x2 days. RX Advil. 04/25/05- Pt better but now has cold.